Given the promising efficacy of new anti-HER2 therapy of antibody-drug conjugates (T-DXd, etc.)in HER2-low breast cancers, it is necessary to explore HER2 ITH in these tumors and its effect on the efficacy of antibody-drug conjugates. This evidence concerns the gene ERBB2 and breast carcinoma.